Mesenchymal Stem Cells: A Friend or Foe in Immune-Mediated Diseases

被引:0
|
作者
Marina Gazdic
Vladislav Volarevic
Nebojsa Arsenijevic
Miodrag Stojkovic
机构
[1] University of Kragujevac,Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences
[2] Spebo Medical,undefined
来源
关键词
Mesenchymal stem cells; Inflammation; Therapy; Immunosuppression; Autoimmunity;
D O I
暂无
中图分类号
学科分类号
摘要
Mesenchymal stem cells (MSCs) are adult, self-renewable, multipotent cells that can be found in almost all postnatal tissues. Because of their capacity for self-renewal and differentiation into tissues of mesodermal origin and due to their immunomodulatory ability, MSCs are used in many preclinical and clinical studies as possible new therapeutic agents for the autoimmune or degenerative diseases treatment. In dependence of inflammatory environment to which they are exposed to, MSCs adopt immunosuppressive or pro-inflammatory phenotype. In the presence of high levels of pro-inflammatory cytokines or through activation of Toll-like receptor (TLR)-3, MSCs adopt an immune-suppressive phenotype and suppress the proliferation, activation and effector function of professional antigen presenting cells (dendritic cells, macrophages, B lymphocytes), T lymphocytes, NK cells, NKT cells, and neutrophils. During the early phase of inflammation, through TLR4 activation and in the presence of low levels of inflammatory cytokines, MSCs adopt a pro-inflammatory phenotype, promote neutrophil and T cell activation and enhance immune response. Here we review the current findings on the immunoregulatory plasticity of MSCs involved in regulation of immune response.
引用
收藏
页码:280 / 287
页数:7
相关论文
共 50 条
  • [41] Adiponectin in inflammatory and immune-mediated diseases
    Fantuzzi, Giamila
    CYTOKINE, 2013, 64 (01) : 1 - 10
  • [42] Immune-Mediated CNS Diseases: a Review
    DeSena A.D.
    Current Physical Medicine and Rehabilitation Reports, 2017, 5 (3) : 134 - 142
  • [43] Approach to Immune-mediated Ocular Diseases
    Knickelbein, Kelly E.
    Lassaline, Mary E.
    VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE, 2024, 40 (02) : 275 - 286
  • [44] ADALIMUMAB IN THE TREATMENT OF IMMUNE-MEDIATED DISEASES
    Lapadula, G.
    Marchesoni, A.
    Armuzzi, A.
    Blandizzi, C.
    Caporali, R.
    Chimenti, S.
    Cimaz, R.
    Cimino, L.
    Gionchetti, P.
    Girolomoni, G.
    Lionetti, P.
    Marcellusi, A.
    Mennini, F. S.
    Salvarani, C.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2014, 27 : 33 - 48
  • [45] Clustering of immune-mediated diseases in sarcoidosis
    Terwiel, Michelle
    Grutters, Jan C.
    van Moorsel, Coline H. M.
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (05) : 539 - 553
  • [46] Inflammatory and Immune-Mediated Cutaneous Diseases
    Quaresma, Juarez A. S.
    Sotto, Mirian N.
    Balato, Anna
    MEDIATORS OF INFLAMMATION, 2017, 2017
  • [47] Reframing Immune-Mediated Inflammatory Diseases
    Boutrid, Nada
    Rahmoune, Hakim
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21):
  • [48] Epigenetics in Immune-Mediated Pulmonary Diseases
    Yu Liu
    Hui Li
    Tao Xiao
    Qianjin Lu
    Clinical Reviews in Allergy & Immunology, 2013, 45 : 314 - 330
  • [49] Immune-mediated inflammatory diseases and psoriasis
    Delaporte, E.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2008, 135 : S269 - S274
  • [50] IMMUNE-MEDIATED EQUINE SKIN DISEASES
    MANNING, T
    SWEENEY, C
    COMPENDIUM ON CONTINUING EDUCATION FOR THE PRACTICING VETERINARIAN, 1986, 8 (12): : 979 - 986